Fig. 1
Performance of the Pan-Cancer Methylation Score Across Blood, Tissues, and Tumor Samples. A Pan-cancer Score (Axe Y) profile in 5,006 healthy blood samples (GSE30870, GSE40279, GSE61496, GSE123914, GSE157131, and GSE55763) and 9,010 cancer samples from 33 different cancer types (ACC, BLCA, BRCA, CESC, CHOL, COAD, DLBC, ESCA, GBM, HNSC, KICH, KIRC, KIRP, LAML, LGG, LIHC, LUAD, LUSC, MESO, OVA, PAAD, PCPG, PRAD, READ, SARC, SKCM, STAD, TGCT, THCA, THYM, UCEC, UCS, UVM) (Table S1, S2). B Comparison of Pan-cancer Score between 5,006 healthy blood samples and 9,010 cancer samples from TCGA. Non-parametric Mann–Whitney U tests were conducted due to the non-normal distribution of the data. Significance level is indicated as p < 0.0001. C ROC analysis of 5,006 healthy blood samples and 9,010 cancer samples from TCGA. Sensitivity and specificity values were selected based on the highest likelihood ratio. The AUC value is shown in the figure. D Pan-cancer Score (Y-axis) profile in 1,695 healthy tissues from NCBI GEO (Table S2), including brain, fallopian tube, breast, cervical mucosa, cervix, colon, endometrium, esophagus, liver, melanocytes, nasopharynx, ovaries, and stomach, as well as 9,010 cancer samples from 33 different cancer types in TCGA. E Pan-cancer Score (Y-axis) profile of 5,006 healthy blood samples and 5,348 cancer samples from NCBI GEO (Table S2), including bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), colon adenocarcinoma (COAD), esophageal carcinoma (ESCA), glioblastoma multiforme (GBM), high-grade serous ovarian carcinoma (HGSOC), head and neck squamous cell carcinoma (HNSC), kidney cancers (KIDNEY), acute myeloid leukemia (LAML), liver hepatocellular carcinoma (LIHC), oral tongue squamous cell carcinoma (OTSCC), ovarian serous cystadenocarcinoma (OVA), pancreatic adenocarcinoma (PAAD), primary central nervous system lymphoma (PCNSL), prostate adenocarcinoma (PRAD), sarcoma (SARC), skin cutaneous melanoma (SKCM), stomach adenocarcinoma (STAD), and uterine corpus endometrial carcinoma (UCEC).
